Follow
Dandan Xing Xu
Dandan Xing Xu
SolveBio
Verified email at solvebio.com - Homepage
Title
Cited by
Cited by
Year
Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance
D Stetson, A Ahmed, X Xu, BRB Nuttall, TJ Lubinski, JH Johnson, ...
JCO Precision Oncology 3, 1-9, 2019
1562019
An integrated morphological and molecular approach to a new species description in the Trypanosomatidae: the case of Leptomonas podlipaevi n. sp., a parasite of Boisea …
V Yurchenko, J LUKEŠ, X Xu, DA Maslov
Journal of Eukaryotic Microbiology 53 (2), 103-111, 2006
692006
Discovery and barcoding by analysis of spliced leader RNA gene sequences of new isolates of Trypanosomatidae from Heteroptera in Costa Rica and Ecuador
DA Maslov, SJ Westenberger, X Xu, DA Campbell, NR Sturm
Journal of Eukaryotic Microbiology 54 (1), 57-65, 2007
612007
Variants at IRX4 as prostate cancer expression quantitative trait loci
X Xu, WM Hussain, J Vijai, K Offit, MA Rubin, F Demichelis, RJ Klein
European Journal of Human Genetics 22 (4), 558-563, 2014
462014
Successes of genome-wide association studies
RJ Klein, X Xu, S Mukherjee, J Willis, J Hayes
Cell 142 (3), 350-351, 2010
432010
Polymorphisms at the microseminoprotein-β locus associated with physiologic variation in β-microseminoprotein and prostate-specific antigen levels
X Xu, C Valtonen-André, C Sävblom, C Halldén, H Lilja, RJ Klein
Cancer epidemiology, biomarkers & prevention 19 (8), 2035-2042, 2010
402010
Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing
X Wang, JE Hayes, X Xu, X Gao, D Mehta, HG Lilja, RJ Klein
Gene 768, 145265, 2021
172021
Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB
M Bicak, X Wang, X Gao, X Xu, RM Väänänen, P Taimen, H Lilja, ...
Human molecular genetics 29 (10), 1581-1591, 2020
132020
Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance. JCO Precis Oncol. 2019
D Stetson, A Ahmed, X Xu, BRB Nuttall, TJ Lubinski, JH Johnson
5
Genetic and functional investigation of germline JAK2 alleles that predispose to myeloproliferative neoplasms
AM Schram, X Xu, O Kilpivaara, S Mukherjee, AD Viny, O Guryanova, ...
Blood 118 (21), 124, 2011
32011
Validation of prostate cancer risk variants by CRISPR/Cas9 mediated genome editing
X Wang, JE Hayes, X Xu, X Gao, D Mehta, HG Lilja, RJ Klein
bioRxiv, 337022, 2018
12018
Functional characterization of common prostate cancer risk variants
X Xu
Weill Medical College of Cornell University, 2014
12014
Discovery and" bar-coding" of new species of the trypanosomatidae by the analysis of spliced leader RNA gene sequences in environmental samples.
DA Maslov, X Xu, S Westenberger, VA Yurchenko, J Lukes, NR Sturm, ...
JOURNAL OF EUKARYOTIC MICROBIOLOGY 54 (2), 48S-48S, 2007
12007
Validation of prostate cancer risk variants by CRISPR/Cas9 mediated genome editing at the MSMB locus
X Wang, J Hayes, X Xu, D Mehtad, X Gao, H Lilja, R Klein
Cancer Research 77 (13_Supplement), 1444-1444, 2017
2017
Comprehensive analysis to identify functional basis of prostate cancer risk SNPs
M Middha, X Xu, RM Vaananen, J Hayes, P Taimen, X Gao, HG Lilja, ...
Cancer Research 76 (14_Supplement), 2566-2566, 2016
2016
Transcriptional regulation and prostate cancer risk loci.
RJ Klein, X Xu, W Hussain, J Farber, RM Vaananen, P Taimen, J Vijai, ...
Journal of Clinical Oncology 31 (15_suppl), 1554-1554, 2013
2013
Genetic and Functional Investigation of Germline JAK2 Alleles That Predispose to Myeloproliferative Neoplasms
AM Schrami, X Xu, O Kilpivaara, S Mukherjee, AD Viny, O Guryanova, ...
BLOOD 118 (21), 60-61, 2011
2011
Discovery and Barcoding by Analysis of Spliced Leader RNA Gene Sequences of New Isolates of Trypanosomatidae
An Integrated Morphological and Molecular Approach to a New Species Description in the Trypanosomatidae: the Case of Leptomonas podlipaevi n. sp., a Parasite of Boisea …
The system can't perform the operation now. Try again later.
Articles 1–19